The DOI matches its Crossref record; 53 of the 54 references it cites were found in a registry or an index.
Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines
Open accessAbstract
The Adult Treatment Panel III (ATP III) of the National Cholesterol Education Program issued an evidence-based set of guidelines on cholesterol management in 2001. Since the publication of ATP III, 5 major clinical trials of statin therapy with clinical end points have been published. These trials addressed issues that were not examined in previous clinical trials of cholesterol-lowering therapy. The present document reviews the results of these recent trials and assesses their implications for cholesterol management. Therapeutic lifestyle changes (TLC) remain an essential modality in clinical management. The trials confirm the benefit of cholesterol-lowering therapy in high-risk patients and support the ATP III treatment goal of low-density lipoprotein cholesterol (LDL-C) <100 mg/dL. They support the inclusion of patients with diabetes in the high-risk category and confirm the benefits of LDL-lowering therapy in these patients. They further confirm that older persons benefit from therapeutic lowering of LDL-C. The major recommendations for modifications to footnote the ATP III treatment algorithm are the following. In high-risk persons, the recommended LDL-C goal is <100 mg/dL, but when risk is very high, an LDL-C goal of <70 mg/dL is a therapeutic option, ie, a reasonable clinical strategy, on the basis of available clinical trial evidence. This therapeutic option extends also to patients at very high risk who have a baseline LDL-C <100 mg/dL. Moreover, when a high-risk patient has high triglycerides or low high-density lipoprotein cholesterol (HDL-C), consideration can be given to combining a fibrate or nicotinic acid with an LDL-lowering drug. For moderately high-risk persons (2+ risk factors and 10-year risk 10% to 20%), the recommended LDL-C goal is <130 mg/dL, but an LDL-C goal <100 mg/dL is a therapeutic option on the basis of recent trial evidence. The latter option extends also to moderately high-risk persons with a baseline LDL-C of 100 to 129 mg/dL. When LDL-lowering drug therapy is employed in high-risk or moderately high-risk persons, it is advised that intensity of therapy be sufficient to achieve at least a 30% to 40% reduction in LDL-C levels. Moreover, any person at high risk or moderately high risk who has lifestyle-related risk factors (eg, obesity, physical inactivity, elevated triglycerides, low HDL-C, or metabolic syndrome) is a candidate for TLC to modify these risk factors regardless of LDL-C level. Finally, for people in lower-risk categories, recent clinical trials do not modify the goals and cutpoints of therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The use of combination fibrate–statin therapy in such patients is consistent with current guidelines that recommend treatment for patients with hypertriglyceridemia and low HDL cholesterol levels that persist despite statin therapy.25”
From Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus (2010) · cites this paper as [25]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“According to practice guidelines in place at the time of patient enrollment in IMPROVE-IT, treatment of hypercholesterolemia was based on lowering LDL cholesterol to target levels, 20,21 which were set on the basis of a patient's risk of cardiovascular events.”
From Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes (2015) · cites this paper as [20]
In the citing paper
“Statins are currently the most effective agents available for managing dyslipidemia and have been shown to reduce CV events in a wide variety of patient populations [10,25,31].”
In the citing paper
“Statins are currently the most effective agents available for managing dyslipidemia and have been shown to reduce CV events in a wide variety of patient populations [10,25,31].”
In the citing paper
“Assiduous attention to abnormalities other than hyperglycemia that accompany type 2 diabetes, such as hypertension and dyslipidaemia, has been shown to improve microvascular and cardiovascular complications.”
From Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy (2009) · cites this paper as [21]
In the citing paper
“Nevertheless, measurement and treatment of blood lipids, blood pressure, and glucose levels have became the major emphases for cardiovascular risk reduction.”
From Beyond Established and Novel Risk Factors: Lifestyle Risk Factors for Cardiovascular Disease (2008) · cites this paper as [25]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,944
Self-citationExpert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
Grundy, S. M., Becker, D. M., Clark, L. T., Cooper, R., Denke, M. A., Howard, J. L., Hunninghake, D. B., Illingworth, D. R., Luepker, R. V., McBride, P. E., et al. (2002) · Civil War Book Review · Cited by 12,198
Self-citationOLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
Pearson, T. A., Mensah, G. A., Alexander, R. W., Anderson, J. L., Cannon, R. O., Criqui, M., Fadl, Y. Y., Fortmann, S. P., Hong, Y., Myers, G. L., et al. (2003) · Circulation · doi:10.1161/01.cir.0000052939.59093.45 · Cited by 6,401
Self-citation
Cited by
Sorted by citations
Items 801–900 of 1,060
Sattar, N. A., Ginsberg, H. N., Ray, K. K., Chapman, M. J., Arca, M., Averna, M. R., Betteridge, D. J., Bhatnagar, D., Bilianou, E., Carmena, R., et al. (2014) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2014.04.001 · Cited by 99
Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis
Engel, S. S., Golm, G. T., Shapiro, D., Davies, M. J., Kaufman, K. D., & Goldstein, B. J. (2013) · Cardiovascular Diabetology · doi:10.1186/1475-2840-12-3 · Cited by 98
Brautbar, A., Ballantyne, C. M., Lawson, K., Nambi, V., Chambless, L. E., Folsom, A. R., Willerson, J. T., & Boerwinkle, E. (2009) · Circulation Cardiovascular Genetics · doi:10.1161/circgenetics.108.817338 · Cited by 98
Amirkalali, B., Fakhrzadeh, H., Sharifi, F., Kelishadi, R., Zamani, F., Asayesh, H., Safiri, S., Samavat, T., & Qorbani, M. (2015) · Iranian Red Crescent Medical Journal · doi:10.5812/ircmj.24723 · Cited by 98
Doroodchi, H., Abdolrasulnia, M., Foster, J. A., Foster, E., Turakhia, M. P., Skelding, K. A., Sagar, K. B., & Casebeer, L. L. (2008) · BMC Family Practice · doi:10.1186/1471-2296-9-42 · Cited by 98
Hou, R., & Goldberg, A. C. (2009) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2008.11.007 · Cited by 100
Emerging Therapies Targeting High-Density Lipoprotein Metabolism and Reverse Cholesterol Transport
Duffy, D., & Rader, D. J. (2006) · Circulation · doi:10.1161/circulationaha.105.593855 · Cited by 101
Paraskevas, K. I., Liapis, C. D., Hamilton, G., & Mikhailidis, D. P. (2006) · European Journal of Vascular and Endovascular Surgery · doi:10.1016/j.ejvs.2006.03.009 · Cited by 97
Managing the underestimated risk of statin-associated myopathy
Rallidis, L. S., Fountoulaki, K., & ANASTASIOU‐NANA, M. I. (2011) · International Journal of Cardiology · doi:10.1016/j.ijcard.2011.07.048 · Cited by 99
Akyüz, Ü., Yeşıl, A., & Yilmaz, Y. N. (2014) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365521.2014.983160 · Cited by 97
Current therapies for lowering lipoprotein (a)
van Capelleveen, J. C., van der Valk, F. M., & Stroes, E. S. G. (2015) · Journal of Lipid Research · doi:10.1194/jlr.r053066 · Cited by 97
Analysis of biomarker data: logs, odds ratios, and receiver operating characteristic curves
Grund, B., & Sabin, C. A. (2010) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0b013e32833ed742 · Cited by 97
Five common gene variants identify elevated genetic risk for coronary heart disease
Bare, L. A., Morrison, A. C., Rowland, C. M., Shiffman, D., Luke, M. M., Iakoubova, O. A., Kane, J. P., Malloy, M. J., Ellis, S. G., Pankow, J. S., et al. (2007) · Genetics in Medicine · doi:10.1097/gim.0b013e318156fb62 · Cited by 97
Shiraya, S., Miyake, T., Aoki, M., Fujiwara, Y., Ohgi, S., Nishimura, M., Ogihara, T., & Morishita, R. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2008.03.020 · Cited by 97
Bays, H. E., Braeckman, R. A., Ballantyne, C. M., Kastelein, J. J., Otvos, J. D., Stirtan, W. G., & Soni, P. N. (2012) · Journal of clinical lipidology · doi:10.1016/j.jacl.2012.07.001 · Cited by 94
Vaidya, D. M., Yanek, L. R., Moy, T. F., Pearson, T. A., Becker, L. C., & Becker, D. M. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.06.031 · Cited by 96
Li, Y., Yang, P., Kong, W., Wang, Y., Hu, C.-Q., Zuo, Z.-Y., Wang, Y., Gao, H., Gao, L., Feng, Y., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm801157z · Cited by 96
Katcher, H. I., Hill, A. M., Lanford, J. L., Yoo, J. S., & Kris‐Etherton, P. M. (2009) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2008.11.010 · Cited by 97
Caselli, S., Canali, E., Foschi, M. L., Santini, D., Angelantonio, E. D., Pandian, N. G., & Castro, S. D. (2009) · European Journal of Echocardiography · doi:10.1093/ejechocard/jep198 · Cited by 96
Shea, J. L., Randell, E. W., & Sun, G. (2010) · Obesity · doi:10.1038/oby.2010.174 · Cited by 94
Bogazzi, F., Buralli, S., Manetti, L., Raffaelli, V., Cigni, T., Lombardi, M., Boresi, F., Taddei, S., Salvetti, A., & Martino, E. (2008) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2008.01779.x · Cited by 96
Wassink, A. M. J., van der Graaf, Y., Olijhoek, J. K., Visseren, F. L. J., & for the SMART Study Group (2007) · European Heart Journal · doi:10.1093/eurheartj/ehm582 · Cited by 94
Lloyd‐Jones, D. M., Huffman, M. D., Karmali, K. N., Sanghavi, D. M., Wright, J. S., Pelser, C. B., Gulati, M., Masoudi, F. A., & Goff, D. C. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.10.018 · Cited by 99
Guyton, J. R., Brown, B. G., Fazio, S., Polis, A., Tomassini, J. E., & Tershakovec, A. M. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.03.003 · Cited by 91
Leiter, L. A., Lundman, P., da Silva, P. M., Drexel, H., Jünger, C., Gitt, A. K., & on behalf of the DYSIS investigators (2011) · Diabetic Medicine · doi:10.1111/j.1464-5491.2011.03360.x · Cited by 95
Venturini, D., Simão, A. N. C., Urbano, M. R., & Dichi, I. (2015) · Nutrition · doi:10.1016/j.nut.2014.12.016 · Cited by 100
Dyslipidemia in South Asian patients
Enas, E. A., Chacko, V., Pazhoor, S. G., Chennikkara, H., & Devarapalli, H. P. (2007) · Current Atherosclerosis Reports · doi:10.1007/s11883-007-0047-y · Cited by 95
Klop, B., Proctor, S. D., Mamo, J. C. L., Botham, K. M., & Cabezas, M. C. (2011) · International Journal of Vascular Medicine · doi:10.1155/2012/947417 · Cited by 96
Clinical Decision Support Systems and Prevention
Njie, G. J., Proia, K. K., Thota, A. B., Finnie, R. K. C., Hopkins, D. P., Banks, S. M., Callahan, D. B., Pronk, N. P., Rask, K. J., Lackland, D. T., et al. (2015) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2015.04.006 · Cited by 101
Bogazzi, F., Battolla, L., Spinelli, C., Rossi, G., Gavioli, S., Bello, V. D., Cosci, C., Sardella, C., Volterrani, D., Talini, E., et al. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1213 · Cited by 95
Charlton-Menys, V., Betteridge, D. J., Colhoun, H., Fuller, J., France, M., Hitman, G. A., Livingstone, S. J., Neil, H. A. W., Newman, C. B., Szarek, M., et al. (2009) · Clinical Chemistry · doi:10.1373/clinchem.2008.111401 · Cited by 94
Costabile, A., Bergillos-Meca, T., Rasinkangas, P., Korpela, K., de Vos, W. M., & Gibson, G. R. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01443 · Cited by 94
Blazing, M. A., Giugliano, R. P., Cannon, C. P., Musliner, T. A., Tershakovec, A. M., White, J. A., Reist, C., McCagg, A., Braunwald, E., & Califf, R. M. (2014) · American Heart Journal · doi:10.1016/j.ahj.2014.05.004 · Cited by 96
Emotional stressors trigger cardiovascular events
Schwartz, B. G., French, W. J., Mayeda, G. S., Burstein, S., Economides, C., Bhandari, A. K., Cannom, D. S., & Kloner, R. A. (2012) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2012.02920.x · Cited by 94
Mattoo, V., Eckland, D. J. A., Widel, M., Durán, S., Fajardo, C., Strand, J., Knight, D., Grossman, L. D., Oakley, D., & Tan, M. H. (2005) · Clinical Therapeutics · doi:10.1016/j.clinthera.2005.05.005 · Cited by 94
Chung, S. W., Park, H., Kwon, J., Choe, G. Y., Kim, S. H., & Oh, J. H. (2016) · The American Journal of Sports Medicine · doi:10.1177/0363546515627816 · Cited by 94
2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: Executive Summary
Hillis, L. D., Smith, P. K., Anderson, J. L., Bittl, J. A., Bridges, C. R., Byrne, J. G., Cigarroa, J. E., DiSesa, V. J., Hiratzka, L. F., Hutter, A. M., et al. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.08.008 · Cited by 98
Verbreitung von Fettstoffwechselstörungen bei Erwachsenen in Deutschland
Scheidt‐Nave, C., Du, Y., Knopf, H., Schienkiewitz, A., Ziese, T., Nowossadeck, E., Gößwald, A., & Busch, M. A. (2013) · Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz · doi:10.1007/s00103-013-1670-0 · Cited by 95
The Inverse Benefit Law: How Drug Marketing Undermines Patient Safety and Public Health
Brody, H. A., & Light, D. W. (2011) · American Journal of Public Health · doi:10.2105/ajph.2010.199844 · Cited by 93
Peripheral artery disease. Part 1: clinical evaluation and noninvasive diagnosis
Lau, J. F., Weinberg, M. D., & Olin, J. W. (2011) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2011.66 · Cited by 94
Eliasson, B., Cederholm, J., Eeg‐Olofsson, K., Svensson, A.-M., Zethelius, B., Guðbjörnsdóttir, S., & Register, O. B. O. T. N. D. (2011) · Diabetes Care · doi:10.2337/dc11-0209 · Cited by 93
Mazokopakis, E. E., Starakis, I., Papadomanolaki, M. G., Mavroeidi, N., & Ganotakis, E. S. (2013) · Journal of the Science of Food and Agriculture · doi:10.1002/jsfa.6261 · Cited by 94
Statins and its hepatic effects: Newer data, implications, and changing recommendations
José, J. (2015) · Journal of Pharmacy And Bioallied Sciences · doi:10.4103/0975-7406.171699 · Cited by 93
Treatment With Ezetimibe Plus Low-Dose Atorvastatin Compared With Higher-Dose Atorvastatin Alone
Piorkowski, M., Fischer, S., Stellbaum, C., Jaster, M., Martus, P., Morguet, A. J., Schultheiss, H., & Rauch, U. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.10.064 · Cited by 93
Grundy, S. M. (2005) · Circulation · doi:10.1161/circulationaha.105.557652 · Cited by 92
Self-citationJenkins, D. J. A., Kendall, C. W. C., Vuksan, V., Faulkner, D., Augustin, L. S. A., Mitchell, S., Ireland, C., Srichaikul, K., Mirrahimi, A., Chiavaroli, L., et al. (2014) · Diabetes Care · doi:10.2337/dc13-2990 · Cited by 91
Handelsman, Y., Mechanick, J. I., Blonde, L., Grunberger, G., Bloomgarden, Z. T., Bray, G. A., Dagogo-Jack, S. E., Davidson, J. A., EINHORN, D. F., Ganda, O. P., et al. (2011) · Endocrine Practice · doi:10.4158/ep.17.2.287 · Cited by 92
Toth, P. P., & Banach, M. (2019) · Methodist DeBakey Cardiovascular Journal · doi:10.14797/mdcj-15-1-23 · Cited by 99
High Sensitivity C-reactive Protein (hsCRP) and its Implications in Cardiovascular Outcomes
Denegri, A., & Boriani, G. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200717090334 · Cited by 98
Bonnet, J., McPherson, R., Tedgui, A., Simoneau, D., Nozza, A., Martineau, P., & Davignon, J. (2008) · Clinical Therapeutics · doi:10.1016/j.clinthera.2008.12.023 · Cited by 92
LDL Cholesterol: The Lower the Better
Martin, S. S., Blumenthal, R. S., & Miller, M. J. (2012) · Medical Clinics of North America · doi:10.1016/j.mcna.2012.01.009 · Cited by 94
Use of Ezetimibe in the United States and Canada
Jackevicius, C. A., Tu, J. V., Ross, J. S., Ko, D. T., & Krumholz, H. M. (2008) · New England Journal of Medicine · doi:10.1056/nejmsa0801461 · Cited by 92
Jenkins, D. J. A., Chiavaroli, L., Wong, J. M. W., Kendall, C., Lewis, G. F., Vidgen, E., Connelly, P. W., Leiter, L. A., Josse, R. G., & Lamarche, B. (2010) · Canadian Medical Association Journal · doi:10.1503/cmaj.092128 · Cited by 92
Orozco‐Beltrán, D., Gil-Guillén, V. F., Quirce, F., Navarro-Perez, J., Pineda, M., de la Cámara, A. G., Pita, S., Díez‐Espino, J., Mateos, J., Merino, J., et al. (2007) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2007.01367.x · Cited by 93
Effects of pioglitazone on lipid and lipoprotein metabolism.
Betteridge, D. J. (2007) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2007.00715.x · Cited by 91
Evidence-based goals in LDL-C reduction
Soran, H., Dent, R., & Durrington, P. (2017) · Clinical Research in Cardiology · doi:10.1007/s00392-016-1069-7 · Cited by 92
Ewer, M. S., & Glück, S. (2009) · Cancer · doi:10.1002/cncr.24219 · Cited by 91
Chilibeck, P. D., Vatanparast, H., Pierson, R. A., Case, A. M., Olatunbosun, O. A., Whiting, S. J., Beck, T., Pahwa, P., & Biem, H. J. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1815 · Cited by 95
Zhang, L., Liu, Y., Lu, X. T., Wu, Y. L., Zhang, C., Ji, X. P., Wang, R., Liu, C. X., Feng, J. B., Jiang, H., et al. (2009) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00208.2009 · Cited by 90
Small, dense low‐density‐lipoproteins and the metabolic syndrome
Rizzo, M., & Berneis, K. K. (2006) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.694 · Cited by 94
Puccetti, L., Santilli, F., Pasqui, A. L., Lattanzio, S., Liani, R., Ciani, F., Ferrante, E., Ciabattoni, G., Scarpini, F., Ghezzi, A. R., et al. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.10.006 · Cited by 89
Statin myopathy: Incidence, risk factors, and pathophysiology
Sewright, K. A., Clarkson, P. M., & Thompson, P. D. (2007) · Current Atherosclerosis Reports · doi:10.1007/s11883-007-0050-3 · Cited by 90
Ladapo, J. A., Jaffer, F. A., Hoffmann, U., Thomson, C. C., Bamberg, F., Dec, G. W., Cutler, D., Weinstein, M. C., & Gazelle, G. S. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.10.012 · Cited by 89
Clearfield, M. B., Amerena, J. V., Bassand, J., García, H. R. H., Miller, S. S., Sosef, F., Palmer, M. K., & Bryzinski, B. S. (2006) · Trials · doi:10.1186/1745-6215-7-35 · Cited by 91
Anderson, J. L. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.04.015 · Cited by 89
Cordero, A., Andrés, E., Ordoñez, B., León, M., Laclaustra, M., Grima, A., Luengo, E., Moreno, J., Bes, M., Pascual, I., et al. (2009) · American Journal of Cardiology · doi:10.1016/j.amjcard.2009.07.008 · Cited by 97
Leiter, L. A., Bays, H. E., Conard, S. E., Bird, S. R., Rubino, J., Hanson, M. E., Tomassini, J. E., & Tershakovec, A. M. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.09.076 · Cited by 90
Keating, G. M. (2011) · American Journal of Cardiovascular Drugs · doi:10.2165/11207690-000000000-00000 · Cited by 90
Steinberg, B. A., Bhatt, D. L., Mehta, S. R., Poole-Wilson, P. A., O’Hagan, P., Montalescot, G., Ballantyne, C. M., & Cannon, C. P. (2008) · American Heart Journal · doi:10.1016/j.ahj.2008.05.020 · Cited by 90
Cannon, C. P., Dansky, H. M., Davidson, M. H., Gotto, A. M., Brinton, E. A., Gould, A. L., Stepanavage, M. E., Liu, S. X., Shah, S., Rubino, J., et al. (2009) · American Heart Journal · doi:10.1016/j.ahj.2009.07.028 · Cited by 90
Ballantyne, C. M., Davidson, M. H., McKenney, J. M., Keller, L. H., Bajorunas, D. R., & Karas, R. H. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.02.092 · Cited by 90
Metabolic syndrome and incidence of liver and breast cancers in Japan
Osaki, Y., Taniguchi, S., Tahara, A., Okamoto, M., & Kishimoto, T. (2011) · Cancer Epidemiology · doi:10.1016/j.canep.2011.03.007 · Cited by 90
Sedentary lifestyle in middle-aged women is associated with severe menopausal symptoms and obesity
Blümel, J. E., Fica, J., Chedraui, P. A., Mezones‐Holguín, E., Zúñiga, M. C., Witis, S., Vallejo, M. S., Tserotas, K., Sánchez, H., Onatra, W., et al. (2016) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000000575 · Cited by 90
Modifying Risk Factors in the Management of Erectile Dysfunction: A Review
DeLay, K. J., Haney, N. M., & Hellstrom, W. J. G. (2016) · The World Journal of Men s Health · doi:10.5534/wjmh.2016.34.2.89 · Cited by 97
KONES, R. J. (2013) · Vascular Health and Risk Management · doi:10.2147/vhrm.s37119 · Cited by 91
NLA Task Force on Statin Safety - 2014 update
Jacobson, T. A. (2014) · Journal of clinical lipidology · doi:10.1016/j.jacl.2014.03.003 · Cited by 91
Doğru, T., Genç, H., Tapan, S., Aslan, F., Erçin, C. N., Örs, F., Kara, M., Sertoğlu, E., Karslıoğlu, Y., Bağcı, S., et al. (2012) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2012.04460.x · Cited by 90
Voils, C. I., Coffman, C. J., Yancy, W. S., Weinberger, M., Jeffreys, A. S., Datta, S., Kovac, S. H., McKenzie, J., Smith, R. C., & Bosworth, H. B. (2012) · Preventive Medicine · doi:10.1016/j.ypmed.2012.11.001 · Cited by 89
Rao, G., & Pandya, P. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.08.055 · Cited by 89
Costet, P., Hoffmann, M. M., Cariou, B., Guyomarch, B., Konrad, T., & Winkler, K. E. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.05.027 · Cited by 92
Diabetes guidelines: easier to preach than to practise?
Bryant, W., Greenfield, J. R., Chisholm, D. J., & Campbell, L. V. (2006) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2006.tb00583.x · Cited by 88
Metabolic syndrome in drug-naïve and drug-free patients with schizophrenia and in their siblings
Darçın, A. E., Çavuş, S. Y., Dılbaz, N., Kaya, H., & Dogan, E. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2015.05.004 · Cited by 89
Update on statin-mediated anti-inflammatory activities in atherosclerosis
Montecucco, F., & Mach, F. (2009) · Seminars in Immunopathology · doi:10.1007/s00281-009-0150-y · Cited by 91
Stefanović, A., Kotur‐Stevuljević, J., Spasić, S., Bogavac‐Stanojević, N., & Bujišić, N. (2007) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2007.07.019 · Cited by 91
Maddox, T. M., Ho, P. M., Roe, M. T., Dai, D., Tsai, T. T., & Rumsfeld, J. S. (2010) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.109.906214 · Cited by 89
Dyslipidemia related to antiretroviral therapy.
Estrada, E., & Portilla, J. (2011) · PubMed · Cited by 89
Walldius, G., & Jungner, I. (2004) · European Heart Journal · doi:10.1093/eurheartj/ehi077 · Cited by 88
Mesa, R. A., Verstovšek, S., Gupta, V. K., Mascarenhas, J. O., Atallah, E. L., Burn, T. C., Sun, W. Y., Sandor, V. A., & Gotlib, J. R. (2014) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2014.12.008 · Cited by 91
Barnes, V. A., & Orme‐Johnson, D. W. (2012) · Current Hypertension Reviews · doi:10.2174/157340212803530411 · Cited by 89
Predictors of progression in atherosclerosis over 2 years in systemic lupus erythematosus
Kiani, A. N., Post, W. S., Magder, L. S., & Petri, M. (2011) · Rheumatology · doi:10.1093/rheumatology/ker285 · Cited by 89
Gamboa, C. M., Colantonio, L. D., Brown, T. M., Carson, A. P., & Safford, M. M. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.116.004264 · Cited by 87
Carrera-Lanestosa, A., Moguel-Ordóñez, Y., & Campos, M. R. S. (2017) · Journal of Medicinal Food · doi:10.1089/jmf.2016.0171 · Cited by 88
Prolonged-Release Nicotinic Acid
McCormack, P. L., & Keating, G. M. (2005) · Drugs · doi:10.2165/00003495-200565180-00014 · Cited by 88
CHENG, A. Y. Y., & Leiter, L. A. (2006) · Current Opinion in Cardiology · doi:10.1097/01.hco.0000231412.15049.fb · Cited by 88
Mulhall, J. P., Telöken, P., Brock, G. B., & Kim, E. (2006) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2006.00286.x · Cited by 87
Califf, R. M., Lokhnygina, Y. V., Cannon, C. P., Stepanavage, M. E., McCabe, C. H., Musliner, T. A., Pasternak, R. C., Blazing, M. A., Giugliano, R. P., Harrington, R. A., et al. (2010) · American Heart Journal · doi:10.1016/j.ahj.2010.03.004 · Cited by 87
Self-citationThe influence of age and body mass index on the metabolic syndrome and its components
Alexander, C. M., Landsman, P. B., & Grundy, S. M. (2007) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2006.00695.x · Cited by 88
Self-citationWoolf, K., Reese, C. E., Mason, M., Beaird, L., Tudor-Locke, C. E., & Vaughan, L. A. (2008) · Journal of the American Dietetic Association · doi:10.1016/j.jada.2008.03.015 · Cited by 89
Voora, D., Shah, S. H., Reed, C. R., Zhai, J., Crosslin, D. R., Messer, C. J., Salisbury, B. A., & Ginsburg, G. S. (2008) · Circulation Cardiovascular Genetics · doi:10.1161/circgenetics.108.795013 · Cited by 87
Metadata
- Authors
- Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J.
- Affiliations
- American College of Cardiology (US)
- Venue
- Circulation
- Published
- 2004-07-13
- Volume
- 110
- Issue
- 2
- Pages
- 227-239
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2106343349
- Cited by
- 6,902
- References
- 54
- Citations by year
- 2026: 32 · 2025: 44 · 2024: 72 · 2023: 71 · 2022: 85 · 2021: 100 · 2020: 127 · 2019: 137 · 2018: 152 · 2017: 189 · 2016: 248 · 2015: 324 · 2014: 382 · 2013: 506 · 2012: 489
- FWCI
- 539.21
- Type
- journal article
- Language
- en
- Update notices
- correction (2004-08-10)
- Open access
- bronze
- doi.org
- Locations
- Circulation (publishedVersion)
- PubMed (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- UNC Libraries
- Funders
- American Heart Association
- American College of Cardiology Foundation
- National Heart, Lung, and Blood Institute
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Keywords
- Adult Treatment Panel III, LDL cholesterol targets, statin therapy, cholesterol-lowering therapy, diabetes mellitus, older adults, triglycerides, HDL cholesterol, nicotinic acid, therapeutic lifestyle changes, cardiovascular risk stratification, hypercholesterolemia, metabolic syndrome, cardiovascular disease prevention
- MeSH terms
- Aged, Anticholesteremic Agents, Antihypertensive Agents, Hypolipidemic Agents, Cardiovascular Diseases, Clinical Trials as Topic, Diabetes Mellitus, Humans, Hypercholesterolemia, Hypertension, Cholesterol, LDL, Middle Aged, Myocardial Infarction, Patient Education as Topic, Risk, Risk Factors, Comorbidity, Thrombolytic Therapy, Randomized Controlled Trials as Topic, Practice Guidelines as Topic, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Evidence-Based Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
